Medicamen Biotech shares fall 3.48% as board committee approves allotment of 5,00,000 equity shares
Why did Medicamen Biotech Ltd-$ shares fall today?
Medicamen Biotech Ltd shares declined by 3.48% on Friday, with the stock trading at ₹257.6 as of 01:03 PM. The fall in share price comes after the company announced the outcome of a key meeting held by its Preferential Issue Committee of the Board of Directors on October 23, 2026. Investors appear to have reacted negatively to the news, as the announcement raised concerns about share dilution among existing shareholders.
The company disclosed that the Preferential Issue Committee approved the allotment of 5,00,000 equity shares at an issue price of ₹530 per share, raising an aggregate amount of ₹26,50,00,000. These shares were allotted pursuant to the conversion of 5,00,000 fully convertible warrants. The shares were issued on a preferential basis to Shivalik Rasayan Limited, which falls under the 'Promoter and Promoter Group' category. While the allotment brings in significant capital for the company, the increase in the total number of outstanding shares can reduce the ownership stake of existing shareholders, potentially diluting their value.
The market reaction suggests that shareholders may be wary of the preferential allotment to a promoter group entity, as such transactions often draw scrutiny regarding fairness to minority investors. The sharp price drop of ₹257.6 indicates that the selling pressure was immediate once the disclosure hit the public domain. Investors will now closely watch how Medicamen Biotech deploys the raised capital and whether the promoter group's increased stake translates into long-term value creation for the company.
What does Medicamen Biotech Ltd-$ do?
Medicamen Biotech Limited is a publicly listed company in the biotechnology sector, with its equity shares traded on both BSE Limited under the scrip code 531146 and the National Stock Exchange of India Limited under the symbol MEDICAMEQ. The company operates under the governance of a Board of Directors that includes a dedicated Preferential Issue Committee, which oversees the issuance and allotment of equity shares and convertible instruments as part of the company's capital management activities.
As of October 23, 2026, the company's Preferential Issue Committee approved the allotment of 5,00,000 equity shares resulting from the conversion of 5,00,000 Fully Convertible Warrants at an issue price of Rs. 530 per equity share for cash, reflecting the company's ongoing engagement in structured fundraising and equity issuance activities in compliance with SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. These corporate actions underscore the company's commitment to transparent financial operations and regulatory compliance as a listed entity on Indian stock exchanges.
Medicamen Biotech Ltd-$ Financials
In CroresMedicamen Biotech Ltd reported a revenue of ₹60.65 Crores for the quarter ended March 2026, which declined to ₹47.9 Crores in the quarter ended June 2026, representing a sequential drop of approximately 21%. Similarly, the company's profit declined from ₹3.86 Crores in the March 2026 quarter to ₹2.12 Crores in the June 2026 quarter, a sequential decline of around 45%. The profit decline was notably sharper than the revenue decline, suggesting a compression in profitability margins during the quarter. Overall, both top-line and bottom-line figures exhibited a declining trend between the two reported quarters, indicating a contraction in financial performance in the near term.
Medicamen Biotech Ltd-$ Shareholding Pattern
Promoter holding stands at 40.46% of the total share capital. Foreign Institutional Investors (FIIs) hold 4.49% stake in the company, while Domestic Institutional Investors (DIIs) hold 0.0%. Public shareholders hold the remaining 55.05% stake in Medicamen Biotech Ltd-$.
Medicamen Biotech Ltd-$ FAQs
Q: Why did Medicamen shares fall 3.48% today?
Outcome of the meeting of Preferential Issue Commitee of the Board of Directors of Medicamen Biotech Limited to consider and approve the allotmentb of 5,00,000 Equity Shares pursuant to ..... This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Medicamen Biotech Ltd-$?
As per the latest data, promoters hold 40.46% stake in Medicamen Biotech Ltd-$, while FII holding stands at 4.49%. Domestic institutional investors hold 0.0%, and public shareholders account for 55.05% of the equity.
Q: What is the current stock price of Medicamen Biotech Ltd-$?
Medicamen Biotech Ltd-$ shares are currently trading at ₹257.6, recording a decline of 3.48% from the previous close.
Q: What is the market capitalization of Medicamen Biotech Ltd-$?
The company currently has a market capitalization of ₹349.38 crore, reflecting its valuation in the Indian equity market.